Immunotherapy for Leukemia, Lymphoma, and Multiple Myeloma with Dr. Hearn Jay Cho

Dr. Hearn Jay Cho of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai discusses different immunotherapies used in the treatment of blood cancers and new treatments in development. #CRIsummit #immunotherapy #lylsm https://summit.cancerresearch.org/

00:00- Tamron Hall introduces Dr. Hearn Jay Cho
00:27- Dr. Hearn Jay Cho discusses blood cancer and immunotherapy
12:11- Brian Brewer leads a Q&A from the audience with Dr. Cho

More than 175,000 new cases of leukemia, lymphoma, and multiple myeloma are expected this year in the United States. Fortunately, a revolution in blood cancer treatment has arrived with immune checkpoint blockade and CAR T cell therapies providing new options for patients. Several immunotherapies are already FDA-approved, and ongoing research demonstrates even greater potential for new treatments, especially in adoptive cell therapy.

Questions from the audience for Dr. Cho:
​​- How does it feel to have participated in and witnessed so much change and progress in the field of immuno-oncology in the past couple decades of your career?

Dr. Hearn Jay Cho is an associate professor of medicine at the Icahn School of Medicine at Mount Sinai and an attending physician with the multiple myeloma service at the Mount Sinai Tisch Cancer Institute in New York. His laboratory investigates novel therapies for multiple myeloma in two areas: the interaction between myeloma and the immune system in the tumor microenvironment, and melanoma antigen genes that are correlated with disease progression and play a critical role in treatment resistance. His team is currently conducting studies to identify novel pharmacologic strategies to inhibit these genes in myeloma.

The 2021 CRI Virtual Immunotherapy Patient Summit is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. It was offered free of charge, connecting cancer patients and caregivers with scientific and medical experts. This year’s Summit highlighted the growing implications of immunotherapy for more than 10 cancer types, provided education on the basics of immunotherapy and how clinical trials work, and addressed cancer care disparities. https://www.cancerresearch.org..../en-us/patients/immu

Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org

Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.

• Category

  Multiple Myeloma